NNOX

$2.60

Market ClosedAs of Mar 17, 8:00 PM UTC

Nano-X Imaging Ltd.

Recent News

Exec Edge
Mar 4, 2026

Nanox Collaborates with 3 New Partners to Expand Medical Imaging Solutions Globally

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it is collaborating with three new partners to expand its imaging solutions across the globe. The company is partnering with Australian-based Harrison.ai to add Nanox’s AI solutions to its AI platform and achieve single-integration access to multiple AI vendors, it stated. Nanox said it is also partnering […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 23, 2026

Here's How Tempus AI Is Tapping the Imagining Space

TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 13, 2026

Market Sentiment Around Loss-Making Nano-X Imaging Ltd. (NASDAQ:NNOX)

With the business potentially at an important milestone, we thought we'd take a closer look at Nano-X Imaging Ltd.'s...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Exec Edge
Jan 22, 2026

Nanox Expands Distribution of Nanox.ARC Imaging System to Western Balkans

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it is collaborating with medical device distributor Adriamed to deploy the Nanox.ARC, a digital tomosynthesis system, to healthcare providers across Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will be Nanox’s exclusive partner in the region supervising marketing, distribution, installation and support matters, the company stated. “We […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Dec 11, 2025

Tempus AI's Strategic Push to Expand Beyond Oncology

TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.